Status:
COMPLETED
Effect of Enteral Bovine Lactoferrin in Preterm Infants
Lead Sponsor:
Ain Shams University
Conditions:
Neonatal Disease
Eligibility:
All Genders
1-3 years
Phase:
NA
Brief Summary
There is a preference for using enteral bovine lactoferrin for preterm infants. Lactoferrin is a sialic acid-rich, iron-binding milk glycoprotein, known to have multifunctional health benefits, includi...
Detailed Description
Over 15 million infants are born preterm \< 37 weeks gestation worldwide. Lactoferrin is about 80- kilo dalton kDa glycoprotein composed of 703 amino acid residues and is a member of the transferrin f...
Eligibility Criteria
Inclusion
- Stable preterm neonates
- gestational age less than 35 weeks
- younger than 72 hours at randomization
- have initiated enteral feds.
Exclusion
- 1\. Neonates with underlying gastrointestinal problems that prevent oral intake. 2. Neonates with predisposing conditions that profoundly affect growth and development (chromosomal abnormalities,
- structural brain anomalies,
- severe congenital abnormalities). 3. Neonates with a history of perinatal hypoxia. 4. Neonates with a family background of cow milk allergy. 5. Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake.
Key Trial Info
Start Date :
September 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 20 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06015828
Start Date
September 20 2021
End Date
April 20 2023
Last Update
May 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospitals
Cairo, Cairo Governorate, Egypt, 1825